捷佳偉創(300724.SZ):實控人及其一致行動人等已減持1%的股份
格隆匯9月26日丨捷佳偉創(300724.SZ)公佈,近日,公司收到控股股東、實際控制人左國軍、梁美珍及其一致行動人梁美珍女兒蔣婉同、公司控股股東、實際控制人之一餘仲實際控制的恆興偉業、鼎興偉業出具的《關於股份減持比例達到1%的吿知函》,左國軍、梁美珍、蔣婉同、恆興偉業、鼎興偉業於2021年9月2日至2021年9月24日期間以集中競價及大宗交易方式減持公司股份數量累計為347.7101萬股,佔公司總股本的1.0000%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.